Molecular mechanisms involved in human platelet aggregation by synergistic interaction of platelet-activating factor and 5-hydroxytryptamine

Shah BH, Rasheed H, Rahman IH, Shariff AH, Khan FL, Rahman HB, Hanif S, Saeed SA

Published December 31, 2001 Experimental & molecular medicine
DOI 10.1038/emm.2001.37 PMID 11795484

Abstract

Our recent studies have shown that co-activation of Gq and Gi proteins by 5-hydroxytryptamine (5-HT) and adrenaline show synergism in human platelet aggregation. This study was conducted to examine the mechanism(s) of synergistic interaction of 5-HT and platelet activating factor (PAF) in human platelets. We show that PAF, but not 5-HT, increased platelet aggregation in a concentration-dependent manner. However, low concentrations of 5-HT (2 microM) potentiated platelet aggregation induced by subthreshold concentration of PAF (40 nM) indicating a synergistic interaction between the two agonists and this synergism was blocked by receptor antagonists to either 5-HT or PAF. 5-HT also potentiated the effect of PAF on thromboxane A2 (TXA2) formation and phosphorylation of extracellularly regulated mitogen-activated protein kinases (ERK1/2). The synergism of 5-HT and PAF in platelet aggregation was inhibited by calcium (Ca2+) channel blockers, verapamil and diltiazem, phospholipase C (PLC) inhibitor, U73122, cyclooxygenase (COX) inhibitor, indomethacin, and MEK inhibitor, PD98059. These data suggest that synergistic effect of 5-HT and PAF on human platelet aggregation involves activation of PLC/Ca2+, COX and MAP kinase pathways.

Bukhtiar H Shah, Huma Rasheed, Ibrahim H Rahman, Amir H Shariff, Fatima L Khan, Hina B Rahman, Sara Hanif, Sheikh A Saeed
B Shah, H Rasheed, I Rahman, A Shariff, F Khan, H Rahman, S Hanif, S Saeed
PMID 11795484 11795484 DOI 10.1038/emm.2001.37 10.1038/emm.2001.37 Shah et al. 2001, Shah 2001